Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study (Q39392083)

11 September 2017

title

Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study (English)

1 reference

11 September 2017

0 references

prostatic hypertrophy

1 reference

2

1 reference

11 September 2017

Anna Rita Bentivoglio

series ordinal

4

1 reference

11 September 2017

Alberto Albanese

6

0 references

Gabriele Sganga

series ordinal

5

object named as

Gabriele Sganga

1 reference

11 September 2017

Giorgio Maria

1

1 reference

11 September 2017

Ignazio Massimo Civello

series ordinal

3

1 reference

11 September 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

11 September 2017

1 reference

11 September 2017

volume

62

1 reference

11 September 2017

issue

2

1 reference

11 September 2017

page(s)

259-64; discussion 264-5

1 reference

Benign prostatic hyperplasia. Medical and minimally invasive treatment options

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900477-1

7 January 2021

Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900477-1

7 January 2021

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900477-1

7 January 2021

Treatment of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900477-1

7 January 2021

Benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900477-1

7 January 2021

Medical therapy for benign prostatic hyperplasia: a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900477-1

7 January 2021

EAU Guidelines on benign prostatic hyperplasia (BPH).

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900477-1

7 January 2021

Transurethral resection of the prostate among Medicare beneficiaries in the United States: time trends and outcomes. Prostate Patient Outcomes Research Team (PORT).

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900477-1

7 January 2021

Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900477-1

7 January 2021

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900477-1

7 January 2021

Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900477-1

7 January 2021

A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900477-1

7 January 2021

Anterior rectocele due to obstructed defecation relieved by botulinum toxin.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900477-1

7 January 2021

Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900477-1

7 January 2021

Relief by botulinum toxin of voiding dysfunction due to prostatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900477-1

7 January 2021

Perisphincteric injection of botulinum toxin type A. A treatment option for patients with chronic prostatic pain?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900477-1

7 January 2021

Botox-induced prostatic involution

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900477-1

7 January 2021

Correlation of the American Urological Association symptom index with self-administered versions of the Madsen-Iversen, Boyarsky and Maine Medical Assessment Program symptom indexes. Measurement Committee of the American Urological Association

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900477-1

7 January 2021

The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900477-1

7 January 2021

Using repeated measures of symptom score, uroflowmetry and prostate specific antigen in the clinical management of prostate disease. Benign Prostatic Hyperplasia Treatment Outcomes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900477-1

7 January 2021

Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900477-1

7 January 2021

Benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900477-1

7 January 2021

Neuroendocrine peptides in the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900477-1

7 January 2021

Histopathologic characterization of hereditary benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900477-1

7 January 2021

Prostate stroma: physiology

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900477-1

7 January 2021

10.1016/S0090-4295(03)00477-1

Identifiers

DOI

1 reference

11 September 2017

1 reference